ABSTRACT

Objective: The study aims to perform molecular docking to examine the interaction between propolis compound and SARS-CoV-2 main protease.

Methods: The protein target of this research was the crystal structure of SARS-CoV-2 main protease in complex with an inhibitor N3 (PDB ID: 6LU7). The ligand of this research was the bioactive compounds from Propolis of Tetragonula aff. biroi.

Results: The results showed that propolis compound which has the potential to inhibit SARS-CoV-2 protease activity was Sulabiroins A (binding affinity -8.1 kcal/mol), followed by (2S)-5,7-dihydroxy-4’-methoxy-8-prenylflavanone acid and broussoflavonol F (binding affinity -7.9 kcal/mol) with binding similarity more than 50% compared to N3-main protease interaction.

Conclusion: Molecular docking showed propolis compounds of Tetragonula aff. biroi potential to inhibit SARS-CoV-2 main protease activity. The highest binding affinity presented by Sulabiroins A, following by (2S)-5,7-dihydroxy-4’-methoxy-8-prenylflavanone acid and broussoflavonol F, with values of -8.1 kcal/mol, -7.9 kcal/mol, and -7.9 kcal/mol, respectively, with binding similarity more than 50% compared to N3 and SARS-CoV-2 main protease interaction.

Keywords: COVID-19, SARS-CoV-2 main protease, Propolis compounds, Molecular Docking, Binding affinity

INTRODUCTION

In late December 2019, there was a severe respiratory disease outbreak in Wuhan, China. This disease then spread to other countries, became a global issue and declared as a pandemic by the World Health Organization (WHO). Based on WHO's data, almost 15.3 million cases had been reported as of 24th July 2020 around the world and the amount increases every day. This disease then named coronavirus disease 2019 (COVID-19).

Coronavirus belong to Coronaviridae family and Orthocoronavirinae subfamily [1]. Coronavirus is an enveloped virus with positive single stranded RNA. In 2003, there was associated case, namely severe acute respiratory syndrome (SARS-2003) caused by another beta-coronavirus. Another case related coronavirus was Middle East Respiratory Syndrome (MERS) in 2012. Both SARS-2003 and MERS were caused by coronavirus, the difference was the objects which transmitted the virus. SARS was transmitted from exotic animals in wet markets to humans, whereas MERS is transmitted to humans from camels [2].

Epidemiological investigations then revealed that COVID-19 was caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) [3]. The exact origin, location, and natural host of SARS-CoV-2 is not clear. COVID-19 causes nonspecific symptoms, including fever, dry cough, and fatigue. Many symptoms may be involved, such as respiratory system (sore throat, short of breath, cough, rhinorrhea, hemoptysis, and chest pain), gastrointestinal system (nausea, diarrhea, and vomiting), musculoskeletal system (muscle ache), and neurologic system (headache or confusion) [4].

Currently, there is no validated therapy and no vaccine available for COVID-19. Some treatments are underway, including antiviral drug development for Ebola and SARS as COVID-19 treatment, using COVID-19 patient’s plasma as convalescent therapies. But further trial needed to evaluate the effectiveness of those therapies [5]. Experimental trial needed to find safe and effective therapy for COVID-19 patients. According to several reports, propolis have several biological activities, including antioxidant, anti-inflammatory, antifungal, and antiviral [6-9]. Propolis is a natural resinous substance collected by honey bees from barks and exudates of plant species, mixed with bee enzymes, pollen and wax. The chemical composition of the propolis biologically active compounds depends on the geographical and botanical origin, the type of bees, and the seasons in which propolis is collected [10]. Several compounds within propolis have been identified, including flavonoids, terpenes, phenols and their esters, sugars, hydrocarbons and mineral elements [11].

Sabanovic et al., (2019) revealed that propolis have antiviral activity [9]. It acts at different levels and blocks the replication of certain viruses such as herpes simplex type 1 and 2, adenovirus type 2, influenza virus, human immunodeficiency virus (HIV), and others. Furthermore, Yildirim et al., (2016) reported that Hatay propolis may be a potential drug for the Herpes Simplex Virus infections treatment [11]. The combination between Hatay propolis and acyclovir (standard drug) produce a stronger antiviral effect against HSV-1 and HSV-2 than acyclovir alone. Research by Banskota et al. (2001) showed that propolis can exhibit antiviral activity by causing partial blocking of viral penetration into the cell, affecting the steps in the viral replication cycle, and leading to degradation of the RNA virus before penetration in a cell or after its release into the supernatant [12].

Since the target protein is known, computational study can be operated to determine SARS-CoV-2 potential drug [11, 14]. The study of Yu et al., (2020) found that molecular docking can be used to identify SARS-CoV-2 potential drug that has antiviral activity [1, 3]. It revealed that the main flavonoid of honeysuckle, luteolin can bind to the active sites of the SARS-CoV-2 main protease tightly with lower binding energy than the ligand of the protein crystal structure. Furthermore, molecular docking can be conducted to analyze the propolis compound that has antiviral activity and potential to be SARS-CoV-2 drug. Molecular docking is a computational procedure that aims to predict a macromolecule
(receptor) and a small molecule (ligand) noncovalent binding, so bound conformations and the binding affinity can be determined [13].

This research aims to examine the potential propolis compounds of *Tetragonula aff. biroi* as COVID-19 therapy by molecular docking. The protein target of this research is the crystal structure of SARS-CoV-2 main protease in complex with an inhibitor N3 (PDB ID: 6LU7). There is already an inhibitor in its active site. The ligand of this research is the bioactive compounds from propolis of *Tetragonula aff. biroi*. Bioactive compounds of propolis believed can interact with the crystal structure of SARS-CoV-2 main protease. To determine it, molecular docking is used to identify which compounds are bound into the binding site. The potential propolis compounds show the lowest molecular docking score toward SARS-CoV-2 main protein.

**MATERIALS AND METHODS**

**Hardware instrument**

Specification of laptop in this research is Acer Aspire V5, AMD C-70 APU with Radeon™ HD Graphics 1.00 GHz processor, 2.00 GB of RAM. Windows 8 Pro 32-bit Operating System, x64-based processor.

**Software instrument**

The software used in this research are Visual Molecular Dynamic (VMD, University of Illinois, Urbana-Champaign), PyMOL, Autodock Tools 1.5.6 (The Scripps Research Institute, USA), Autodock Vina (The Scripps Research Institute), MarvinSketch (ChemAxon, Budapest, Hungary), and LigPlot+(EMBL-EBI, UK).

**Propolis compounds selection**

According to Miyata et al. (2020), various compounds were identified from the propolis of stingless bees (*Tetragonula aff. biroi*) (table 1, Compound 1-13) [16, 17]. Meanwhile, Mahadewi et al. (2018) reported that Sulawesi propolis wax contained antifungal compounds (table 1, Compound 14-17) [18]. Furthermore, Sahlan et al. (2019) identified anti-inflammatory compounds from propolis of *Tetragonula sp.*, (table 1, Compound 18-20) [7].

**Protein structure preparation**

The crystal structure of the examined protein was downloaded from RCSB Protein Data Bank (http://www.rcsb.org) in the PDB format. In this study, we obtain the crystal structure of SARS-CoV-2 main protease in complex with an inhibitor N3 (PDB ID: 6LU7). The protein and native ligand then separated using VMD (Hsin et al., 2008), in this case, the native ligand is N3 [20]. The separated file was saved as*.pdb. These files are then loaded to Autodock Tools 1.5.6 to prepare the 3D structure of each protein and native ligand as*.pdbqt file format. The protein preparation, including the addition of polar hydrogens and charges.

### Table 1: Propolis compounds

| No | Compound | Molecular formula | Structure-2D |
|----|----------|-------------------|--------------|
| 1  | Sulabiroins A | C_{22}H_{22}O_{7} | ![Structure-2D](image1) |
| 2  | Sulabiroins B | C_{23}H_{26}O_{7} | ![Structure-2D](image2) |
| 3  | 2',3'-Dihydro-3'-hydroxyxyapuanic acid | C_{25}H_{38}O_{7} | ![Structure-2D](image3) |
| 4  | (−)-Papuanic acid | C_{25}H_{36}O_{6} | ![Structure-2D](image4) |
| 5  | (−)-Isocalolongic Acid | C_{24}H_{34}O_{6} | ![Structure-2D](image5) |
6. Isopapuanic acid \( \text{C}_{25}\text{H}_{36}\text{O}_6 \)

7. Isocalopolyanic acid \( \text{C}_{24}\text{H}_{32}\text{O}_6 \)

8. Glyasperin A \( \text{C}_{25}\text{H}_{26}\text{O}_7 \)

9. Broussoflavonol F \( \text{C}_{25}\text{H}_{26}\text{O}_7 \)

10. (2S)-5,7-Dihydroxy-4'-methoxy-8-prenylflavanone \( \text{C}_{20}\text{H}_{20}\text{O}_5 \)

11. Isorhamnetin \( \text{C}_{16}\text{H}_{12}\text{O}_7 \)

12. (1'S)-2-Trans,4-trans-abscisic acid \( \text{C}_{15}\text{H}_{20}\text{O}_4 \)

13. (1'S)-2-Cis,4-trans-abscisic acid \( \text{C}_{15}\text{H}_{20}\text{O}_4 \)

14. Curcumene \( \text{C}_{15}\text{H}_{22} \)

15. Thymol \( \text{C}_{10}\text{H}_{14}\text{O} \)

16. Tetralin \( \text{C}_{10}\text{H}_{12} \)
Ligand structure preparation

In total 21 ligands used in this research, one native ligand as a control (fig. 1) and 20 propolis compounds (table 1).

The 2D structure of propolis compounds prepared by using Marvin Sketch (Csizmadia, 1999) and converted into 3D structure [21]. All files then saved as *.pdb format and loaded to Autodock Tools 1.5.6 to prepare*.pdbqt file by adding polar hydrogens and charges.

Re-docking

Docking propolis compounds, as a ligand, to the main protease required specific search space. This is the important step to determine the binding site of the ligand within the protein area, hence re-docking have to be done. This step involves separating native ligand and protein then dock it back to its place on protein by setting the size and the center of the search space box [22]. Re-docking and docking simulation performed by AutoDock Vina, automated docking tools with easy operational use, high processing speed and binding mode prediction accuracy [15] for docking and analysis.

RESULTS AND DISCUSSION

Selection of propolis compound

This study focused on identifying propolis compounds of *Tetragonula aff. biroi* that targeted the main protein (Mpro) of SARS-CoV-2. Mpro is a 33.8-kDa protease, it is a coronavirus key enzyme and has a pivotal role in mediating viral replication and transcription functions through extensive proteolytic processing of two replicase polyproteins, pp1a (486 kDa) and pp1ab (790 kDa) (Yang *et al.*, 2003). Its important role makes it an interesting target for developing SARS-CoV-2 potential drugs. From several main protease structures which available at Protein Data Bank, PDB ID 6LU7 was chosen in this research because it has native ligand N3 that bind to the substrate-binding pocket of SARS-CoV-2 main protease. Jin *et al.* (2020) found that N3 showed inhibition activity against SARS-CoV-2 with individual half-maximal effective concentration (EC50) values of 16.77 µM. The selection of 20 propolis compounds in table 1 based on previous researches that have been done.

| Ligand structure preparation | | | |
|---|
| 17 | P-Coumaric acid | C_{9}H_{10}O_{3} |
| 18 | α-Tocopherol succinate | C_{32}H_{52}O_{5} |
| 19 | Deoksi podophyllotoxin | C_{22}H_{22}O_{7} |
| 20 | Xanthoxyletin | C_{15}H_{14}O_{4} |

**Fig. 1: Structure of native ligand N3 (http://www.rcsb.org)**

![Structure of native ligand N3](http://www.rcsb.org)

The 2D structure of propolis compounds prepared by using Marvin Sketch (Csizmadia, 1999) and converted into 3D structure [21]. All files then saved as *.pdb format and loaded to Autodock Tools 1.5.6 to prepare*.pdbqt file by adding polar hydrogens and charges.

Re-docking

Docking propolis compounds, as a ligand, to the main protease required specific search space. This is the important step to determine the binding site of the ligand within the protein area, hence re-docking have to be done. This step involves separating native ligand and protein then dock it back to its place on protein by setting the size and the center of the search space box [22]. Re-docking and docking simulation performed by AutoDock Vina, automated docking tools with easy operational use, high processing speed and binding mode prediction accuracy [15]. Autodock Vina was chosen because of its accuracy is higher than Autodock Tools in term of binding mode predictions [23].

Determining the specific search space in protein involves three criterions; number of points in x, y, z dimension (grid box size), grid box center and grid spacing. Re-docking simulation obtain some poses, the first generally poses the best pose with the lowest docking score. Then Root Mean Square Deviation (RSMD) between native ligand and re-docking result first pose was evaluated using PyMol, Python-based software that can be used for protein-ligand modelling [24]. The result is classified as the accurate one if the RSMD value is less than 2 Å [25]. The re-docking coordinate then used to dock propolis compounds into the protein target.

Docking and analysis

Propolis compounds were docked to each receptor using parameters and coordinates that had been obtained from re-docking simulation. The lowest docking score result was considered as the best pose which used to analyze the interaction between propolis compounds, as a ligand, and protein. The interaction profiles then represented in 2D visualization using LigPlot+. LigPlot+ is an automatic program that generates multiple two-dimensional (2D) diagrams of ligand-protein interactions from docked complexes. It is utilized to identify the interacting residues, hydrogen bonds interaction, and hydrophobic contacts of ligands and the main-chain or side-chain of the protein [26].

**RESULTS AND DISCUSSION**

**Selection of propolis compound**

This study focused on identifying propolis compounds of *Tetragonula aff. biroi* that targeted the main protein (Mpro) of SARS-CoV-2. Mpro is a 33.8-kDa protease, it is a coronavirus key enzyme and has a pivotal role in mediating viral replication and transcription functions through extensive proteolytic processing of two replicase polyproteins, pp1a (486 kDa) and pp1ab (790 kDa) (Yang *et al.*, 2003). Its important role makes it an interesting target for developing SARS-CoV-2 potential drugs. From several main protease structures available at Protein Data Bank, PDB ID 6LU7 was chosen in this research because it has native ligand N3 that binds to the substrate-binding pocket of SARS-CoV-2 main protease. Jin *et al.* (2020) found that N3 showed inhibition activity against SARS-CoV-2 with individual half-maximal effective concentration (EC50) values of 16.77 µM.

The selection of 20 propolis compounds in table 1 based on previous researches that have been done.
Binding site determination

Binding site then became an area where the propolis compounds bind to the protein. Native ligand re-docking obtained mode 1 as the best pose, which had a docking score of -8.4 kcal/mol. The grid box was determined on the active site area, considering the presents of amino acids Thr190, Glu166, Gln192, Gly143, His163, His172, His164, Cys145, Phe140, Phe185, accordance to previous studies with the crystallographic structure of the SARS-CoV-2 main protease [27, 28]. Re-docking evaluation performed by calculating Root-Mean Square Deviation (RMSD) value using Pymol and the result was 1.468 Angstroms. Meanwhile, Andrade et al. (2020) reported that the best confirmation of N3 presented RMSD of 1.94 Angstroms (fig. 2b) [29]. Fig. 2 shows the comparison position between crystallized N3 and re-docking confirmation result.

Docking procedure results of propolis compounds

Molecular docking performed by AutoDock Vina obtain 9 ligand poses with different docking score. AutoDock Vina determines the docking score, also known as binding affinity, automatically [15]. The lowest docking score represented the strongest binding affinity. Docking score results of propolis compounds towards SARS-CoV-2 main protease in complex with an inhibitor N3 showed by table 3. The results present that all compounds bind to amino acid at binding site. The propolis compound which has the lowest docking score was Sulabiroins A, following by (2S)-5,7-dihydroxy-4'-methoxy-8-prenyllavananone and broussoflavonol F, with values of -8.1 kcal/mol, -7.9 kcal/mol, and -7.9 kcal/mol, in succession.

Propolis and SARS-CoV-2 main protease interaction

The interaction between propolis compounds and main protease then analyzed using LigPlot+. The visualization results of three propolis compounds with the lowest docking score are presented in fig. 3. There are two kinds of molecular interactions in the visualization result; dashed lines and arcs. The green dashed lines illustrate hydrogen bonds, the length of the bond showed by the numbers above these lines. The green dashed lines indicate hydrogen bonds, the length of the bond were given above these lines. The green dashed lines illustrate hydrogen bonds, the length of the bond showed by the numbers above these lines. The green dashed lines illustrate hydrogen bonds, the length of the bond showed by the numbers above these lines. Meanwhile, the arcs with spokes radiating toward the ligand atoms mean hydrophobic interactions. Furthermore, ligand structure is represented by purple lines and amino acid residues showed by the brown line.

| No | Propolis compounds                                      | Docking score |
|----|--------------------------------------------------------|---------------|
| 1  | N3 (native ligand)                                      | -8.4          |
| 2  | Sulabiroins A                                           | -8.1          |
| 3  | Broussoflavonol F                                      | -7.9          |
| 4  | (2S)-5,7-dihydroxy-4’-methoxy-8-prenyllavanone       | -7.9          |
| 5  | Sulabiroins B                                          | -7.8          |
| 6  | Glyasperin A                                           | -7.8          |
| 7  | Deoksi podophyllotoxin                                 | -7.4          |
| 8  | Papuanic acid                                          | -7.4          |
| 9  | Isorhamnetin                                           | -7.3          |
| 10 | Isocalolonic acid                                      | -7.2          |
| 11 | 2',3'-dihydroxy-3'-hydroxypapuanic acid                | -7.1          |
| 12 | Isopapuanic acid                                       | -7.0          |
| 13 | Xanthoxyletin                                          | -6.7          |
| 14 | (1'S)-2-trans,4-trans-abscissic acid                   | -6.5          |
| 15 | Isocalopolyanic acid                                   | -6.4          |
| 16 | α-Tocopherol succinate                                 | -6.2          |
| 17 | (1'S)-2-cis,4-trans-abscissic acid                     | -6.0          |
| 18 | Curcumene                                              | -5.5          |
| 19 | P-coumaric acid                                        | -5.1          |
Molecular interaction between amino acid residues of main protease with various ligand represents in table 4. Native ligand N3 formed hydrogen bond with Thr190, Gln189, His41, Ser144, His163, Glu166 and Phe140. Yu et al. (2020) reported that N3 formed a hydrogen bond with Cys145 and Gln189 [30]. N3 also formed hydrophobic interaction with Thr25, Leu27, Leu4, Val13, and Asn142.

The interaction between the three best propolis compounds with SARS-CoV-2 main protease indicated that each compound has a bound to binding site in the main protease. It is enhanced by the binding similarity result that represents each propolis compound has a similarity above 50% compared to N3 and SARS-CoV-2 main protease interaction. Compared with N3-main protease interaction, the interaction of Sulabiroins A, Broussoflavonol F, and (2S)-5,7-dihydroxy-4′-methoxy-8-prenylflavanone with main protease represented the binding similarity of 64%, 59%, and 59%, respectively.

Sulabiroins A did not form hydrogen bond with any residues. It formed hydrophobic interaction with 14 amino acids in the active site region of SARS-CoV-2 main protease instead. Broussoflavonol F represented hydrogen bond with the residues Cys145, Gly143, Gln189, His163, Leu141 and Ser144. Furthermore, (2S)-5,7-dihydroxy-4′-methoxy-8-prenylflavanone displayed five hydrogen interactions with Ser144, Leu141, Gly143, Glu166 and Asp187. It showed interaction with Leu27, which did not interact with other propolis compounds, including N3.

Fig. 3: Interaction visualization of main protease with various ligands. (a) N3; (b) Sulabiroins A; (c) Broussoflavonol F; (d) (2S)-5,7-dihydroxy-4′-methoxy-8-prenylflavanone

Table 4: Molecular interaction of various ligands and main protease

| Ligand                  | Binding analysis | Hydrogen bonding | Hydrophobic interactions | Binding similarity* | Interactions with other residues |
|-------------------------|------------------|------------------|--------------------------|---------------------|---------------------------------|
| N3 (native ligand)      |                  |                  |                          | 100%                | -                               |
| Tetralin                | -                | -                |                          |                     |                                 |
| Thymol                  | -                | -                |                          |                     |                                 |

Table 4: Molecular interaction of various ligands and main protease

(a) N3; (b) Sulabiroins A; (c) Broussoflavonol F; (d) (2S)-5,7-dihydroxy-4′-methoxy-8-prenylflavanone
CONCLUSION

Further studies are needed to determine the efficacy and safety of these propolis compounds for COVID-19 therapy. There are numerous drugs and ongoing medication strategies under clinical trials related with COVID-19 with a hope for avoiding possible threatening of the lives of millions of human beings and providing directions for future research.

ACKNOWLEDGMENT

The authors would like to thank the DRPM Universitas Indonesia for financial support through Grant Program Penelitian Kolaborasi Indonesia 2020 (Grant No: NKB-3145/UN2. RST/HKP.05.00/2020)

FUNDING

The financial support from DRPM Universitas Indonesia

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chinese Med Assoc 2020;83:217-20.
2. Sabir JSM, Lam TTY, Ahmed MMM, Li L, Shen Y, Aba-Abah SEM, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 2016;351:81-4.
3. Al-Tameemi K, Kabakli R. Novel coronavirus (2019-nCoV): disease briefings. Asian J Pharm Clin Res 2020;13:1-3.
4. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843-4.
5. Wang M, Gao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
24. Yuan S, Chan HCS, Hu Z. Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci 2017;7:e1298.
25. Ramírez D, Cabaílofo J. Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules 2018;23:1038-43.
26. Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011;51:2778–86.
27. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020;582:289-93.
28. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020;368:409-12.
29. Andrade BS, Ghosh P, Barh D, Tiwari S, Silva RJS, de Assis Soares WR, et al. Computational screening for potential drug candidates against the SARS-CoV-2 main protease. F1000 Res 2020;9:514.
30. Yu R, Chen L, Lan R, Shen R, Li P. Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents 2020;56:106012.
31. Hsu MF, Kuo CJ, Chang KT, Chang HC, Chou CC, Ko TP, et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 2005;280:31257–66.
32. Singh M, Nagpal M, Singh V, Sharma A, Dhingra Ga, Maman P, Puri V. Covid-19: epidemiology, pathogenicity and global updates. Int J Appl Pharm 2020;12:6-8.